CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia.
Although B chronic lymphocytic leukemia (B-CLL) is characterized by prolonged survival of CD5(+) B cells in vivo, these cells apoptose spontaneously in vitro. The effect of CD5 ligation on apoptosis was studied in 27 newly diagnosed patients with B-CLL, in relation to the expression of surface IgM (sIgM), CD79b, CD38, CD72 and CD19. B cells from 15 patients (group I) were resistant to anti-CD5-induced apoptosis, whereas apoptosis above spontaneous levels was seen in the remaining 12 studied (group II). Group II was then subdivided on the basis of differences in the time required to reach maximum apoptosis: whilst B cells from seven patients underwent apoptosis by 18 h, those from the remaining five needed 36 h to apoptose. The expression of sIgM, CD5, CD79b and CD38 was higher in group II than group I, suggesting that signaling for apoptosis might operate via CD79, and that CD38 expression was required. As shown by flow cytometry and confirmed by Western blotting, apoptosis was associated with a decrease in the ratios of Bcl-2/Bax and Bcl(XL)/Bax, due to an increase in the level of Bax, but no change in that of Bcl-2. This heterogeneous apoptotic response to CD5 ligation offers an explanation for the incomplete success of anti-CD5 monoclonal therapy, and might help identify patients who would respond to such treatment.
Pers
J O
JO
Institut de Synergie des Sciences et de la Santé, Brest University Medical School, Brest, France.
Berthou
C
C
Porakishvili
N
N
Burdjanadze
M
M
Le Calvez
G
G
Abgrall
J F
JF
Lydyard
P M
PM
Youinou
P
P
Jamin
C
C
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology*; D000951:Antigens, Neoplasm / Q000276:immunology / Q000502:physiology*; D017209:Apoptosis / Q000502:physiology*; D001402:B-Lymphocytes / Q000166:cytology*; D015153:Blotting, Western; D018956:CD5 Antigens / Q000276:immunology / Q000502:physiology*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000473:pathology*; D008024:Ligands; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000502:physiology; D014411:Neoplastic Stem Cells / Q000166:cytology*; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis / Q000502:physiology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000502:physiology; D012720:Severity of Illness Index; D015398:Signal Transduction; D014407:Tumor Cells, Cultured / Q000166:cytology*; D051028:bcl-2-Associated X Protein; D051020:bcl-X Protein
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; C494826:BAX protein, human; C494811:BCL2L1 protein, human; D018956:CD5 Antigens; D008024:Ligands; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D051028:bcl-2-Associated X Protein; D051020:bcl-X Protein